Cost of Paid Transplantation Abroad: Possible Donor-Origin Early Multiple Myeloma in a Renal Transplant Recipient Treated Using Bortezomib

Basit Öğe Kaydı
dc.contributor.authorSolak, Y.
dc.contributor.authorAtalay, H.
dc.contributor.authorAnıl, M.
dc.contributor.authorAydoğdu, I.
dc.contributor.authorTonbul, H. Z.
dc.date.accessioned2020-03-26T17:47:40Z
dc.date.available2020-03-26T17:47:40Z
dc.date.issued2010
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractThe incidence of cancer is greater in transplant recipients compared with the general population. Posttransplantation lymphoproliferative disorder (PTLD) is the second most common cancer in these patients. Non-Hodgkin lymphoma is most commonly observed, and multiple myeloma (PTLD-MM) accounts for less than 4% of PTLDs. Most reported PTLD-MM is of recipient origin, and to date, few cases of donor-origin PTLD-MM have been reported. Bortezomib is a protease inhibitor that has been used successfully to treat multiple myeloma. Herein, we describe the case of a patient in whom multiple myeloma developed shortly after paid living-unrelated renal transplantation performed abroad (in Egypt). The patient had no apparent risk factors for PTLD-MM. Thus, it was supposed that PTLD-MM was of donor origin, considering its early development, lack of recipient risk factors, and no available donor medical status. To our knowledge, this report is the first to describe the use of bortezomib in this setting. Although bortezomib plus dexamethasone therapy resulted in hematologic remission, the patient remained dialysis-dependent.en_US
dc.identifier.citationSolak, Y., Atalay, H., Anıl, M., Aydoğdu, I., Tonbul, H. Z., (2010). Cost of Paid Transplantation Abroad: Possible Donor-Origin Early Multiple Myeloma in a Renal Transplant Recipient Treated Using Bortezomib. Transplantation Proceedings, (42), 2813-2815. Doi: 10.1016/j.transproceed.2010.05.164
dc.identifier.doi10.1016/j.transproceed.2010.05.164en_US
dc.identifier.endpage2815en_US
dc.identifier.issn0041-1345en_US
dc.identifier.pmid20832595en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2813en_US
dc.identifier.urihttps://dx.doi.org/10.1016/j.transproceed.2010.05.164
dc.identifier.urihttps://hdl.handle.net/20.500.12395/24743
dc.identifier.volume42en_US
dc.identifier.wosWOS:000281942200079en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorSolak, Y.
dc.institutionauthorAtalay, H.
dc.institutionauthorAnıl, M.
dc.institutionauthorAydoğdu, I.
dc.institutionauthorTonbul, H. Z.
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.titleCost of Paid Transplantation Abroad: Possible Donor-Origin Early Multiple Myeloma in a Renal Transplant Recipient Treated Using Bortezomiben_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
4743.pdf
Boyut:
97.99 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
İç Hastalıkları/Makale Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu